AU2010319680B2 - Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells - Google Patents
Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells Download PDFInfo
- Publication number
- AU2010319680B2 AU2010319680B2 AU2010319680A AU2010319680A AU2010319680B2 AU 2010319680 B2 AU2010319680 B2 AU 2010319680B2 AU 2010319680 A AU2010319680 A AU 2010319680A AU 2010319680 A AU2010319680 A AU 2010319680A AU 2010319680 B2 AU2010319680 B2 AU 2010319680B2
- Authority
- AU
- Australia
- Prior art keywords
- cells
- grp
- mammalian
- div
- cultured
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 95
- 230000002518 glial effect Effects 0.000 title claims abstract description 19
- 210000000130 stem cell Anatomy 0.000 title abstract description 10
- 239000000203 mixture Substances 0.000 title description 4
- 230000002708 enhancing effect Effects 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 207
- 230000006378 damage Effects 0.000 claims abstract description 34
- 210000001130 astrocyte Anatomy 0.000 claims abstract description 31
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 26
- 210000004248 oligodendroglia Anatomy 0.000 claims abstract description 24
- 238000004519 manufacturing process Methods 0.000 claims abstract description 22
- 208000014674 injury Diseases 0.000 claims abstract description 19
- 210000002569 neuron Anatomy 0.000 claims abstract description 19
- 230000003247 decreasing effect Effects 0.000 claims abstract description 18
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 17
- 230000001413 cellular effect Effects 0.000 claims abstract description 17
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 16
- 210000000653 nervous system Anatomy 0.000 claims abstract description 8
- 241000124008 Mammalia Species 0.000 claims description 24
- 230000001537 neural effect Effects 0.000 claims description 22
- 210000000278 spinal cord Anatomy 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 230000004069 differentiation Effects 0.000 claims description 14
- 239000000758 substrate Substances 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 13
- 208000016192 Demyelinating disease Diseases 0.000 claims description 11
- 210000004556 brain Anatomy 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 238000003306 harvesting Methods 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 10
- 206010012305 Demyelination Diseases 0.000 claims description 9
- 210000004748 cultured cell Anatomy 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 7
- 239000002243 precursor Substances 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 6
- 210000000535 oligodendrocyte precursor cell Anatomy 0.000 claims description 6
- 239000006285 cell suspension Substances 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- 238000010257 thawing Methods 0.000 claims description 5
- 239000011324 bead Substances 0.000 claims description 4
- 230000001605 fetal effect Effects 0.000 claims description 4
- 238000002826 magnetic-activated cell sorting Methods 0.000 claims description 3
- 210000000276 neural tube Anatomy 0.000 claims description 3
- 210000004129 prosencephalon Anatomy 0.000 claims description 3
- 238000001574 biopsy Methods 0.000 claims description 2
- 210000003754 fetus Anatomy 0.000 claims description 2
- 230000000052 comparative effect Effects 0.000 claims 1
- 210000004498 neuroglial cell Anatomy 0.000 abstract description 14
- 230000014509 gene expression Effects 0.000 abstract description 12
- 210000003061 neural cell Anatomy 0.000 abstract description 7
- 101001071515 Homo sapiens Gastrin-releasing peptide Proteins 0.000 description 30
- 101000841490 Homo sapiens Unique cartilage matrix-associated protein Proteins 0.000 description 30
- 102000056782 human Ucma Human genes 0.000 description 30
- 210000001519 tissue Anatomy 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 14
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 11
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 11
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 11
- 241000700159 Rattus Species 0.000 description 9
- 238000002513 implantation Methods 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 102000006386 Myelin Proteins Human genes 0.000 description 8
- 108010083674 Myelin Proteins Proteins 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 210000005012 myelin Anatomy 0.000 description 8
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 7
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 7
- 108010057417 polysialyl neural cell adhesion molecule Proteins 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 102000047918 Myelin Basic Human genes 0.000 description 6
- 101710107068 Myelin basic protein Proteins 0.000 description 6
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 4
- 101001107084 Homo sapiens E3 ubiquitin-protein ligase RNF5 Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 102000008730 Nestin Human genes 0.000 description 4
- 108010088225 Nestin Proteins 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000002684 laminectomy Methods 0.000 description 4
- 210000005055 nestin Anatomy 0.000 description 4
- 108010055896 polyornithine Proteins 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 3
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 3
- 201000002775 amyotrophic lateral sclerosis type 15 Diseases 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 230000008045 co-localization Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000011694 lewis rat Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000000274 microglia Anatomy 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000001178 neural stem cell Anatomy 0.000 description 3
- 238000011020 pilot scale process Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000012580 N-2 Supplement Substances 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 101150075516 RAG2 gene Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 238000013394 immunophenotyping Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000009593 lumbar puncture Methods 0.000 description 2
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 208000011403 Alexander disease Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 206010007877 Cell-mediated immune deficiency Diseases 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101100193633 Danio rerio rag2 gene Proteins 0.000 description 1
- 206010067601 Dysmyelination Diseases 0.000 description 1
- 102100021811 E3 ubiquitin-protein ligase RNF5 Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010061431 Glial scar Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 206010027925 Monoparesis Diseases 0.000 description 1
- 101100193635 Mus musculus Rag2 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 101150044441 PECAM1 gene Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- -1 TUJ1 Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 230000002502 anti-myelin effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000010442 axonal sprouting Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26044109P | 2009-11-12 | 2009-11-12 | |
| US61/260,441 | 2009-11-12 | ||
| US32679910P | 2010-04-22 | 2010-04-22 | |
| US61/326,799 | 2010-04-22 | ||
| PCT/US2010/055956 WO2011059952A1 (en) | 2009-11-12 | 2010-11-09 | Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2010319680A1 AU2010319680A1 (en) | 2012-07-05 |
| AU2010319680B2 true AU2010319680B2 (en) | 2014-05-29 |
Family
ID=43991980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010319680A Active AU2010319680B2 (en) | 2009-11-12 | 2010-11-09 | Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10351823B2 (enExample) |
| EP (2) | EP3269803A3 (enExample) |
| JP (2) | JP5952737B2 (enExample) |
| CN (2) | CN102686721B (enExample) |
| AU (1) | AU2010319680B2 (enExample) |
| CA (1) | CA2780541C (enExample) |
| DK (1) | DK2499238T3 (enExample) |
| ES (1) | ES2649396T3 (enExample) |
| NO (1) | NO2499238T3 (enExample) |
| PL (1) | PL2499238T3 (enExample) |
| WO (1) | WO2011059952A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2476376C (en) | 2002-02-15 | 2014-10-21 | Cornell Research Foundation, Inc. | Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells |
| CA2723382A1 (en) | 2008-05-08 | 2009-11-12 | University Of Rochester | Treating myelin diseases with optimized cell preparations |
| EP2954046B1 (en) | 2013-02-06 | 2025-10-15 | University Of Rochester | Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders |
| CA2959691A1 (en) * | 2014-09-26 | 2016-03-31 | The Procter & Gamble Company | Products comprising malodor reduction materials |
| US9724432B2 (en) | 2015-04-30 | 2017-08-08 | University Of Rochester | Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder |
| CN110913689A (zh) | 2017-05-10 | 2020-03-24 | 罗切斯特大学 | 治疗神经精神病症的方法 |
| CN108624560B (zh) * | 2018-06-01 | 2022-04-08 | 南京艾尔普再生医学科技有限公司 | 一种分化培养基及少突胶质前体细胞的制备方法 |
| US10995325B2 (en) | 2019-03-21 | 2021-05-04 | Fornia Biosolutions, Inc. | Additional phytase variants and methods |
| KR102322635B1 (ko) * | 2021-06-11 | 2021-11-05 | 인제대학교 산학협력단 | 말초신경양 미세조직 제조방법 및 이의 용도 |
| WO2023278783A1 (en) * | 2021-06-30 | 2023-01-05 | The Regents Of The University Of California | Methods to generate glial restricted neural progenitor cells and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070037222A1 (en) * | 1997-07-04 | 2007-02-15 | Rao Mahendra S | Lineage restricted glial precursors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2295197A1 (en) | 1999-09-08 | 2001-03-08 | Appleton Papers Inc. | Thermally-responsive record material |
| US6878543B1 (en) * | 1999-10-25 | 2005-04-12 | Nsgene Sa | Cultures of GFAP+ nestin+ cells that differentiate to neurons |
| AR046076A1 (es) * | 2003-07-18 | 2005-11-23 | Otsuka Pharma Co Ltd | Procedimiento para obtener una poblacion homogenea de celulas precursoras de oligodendrocitos y poblacion obtenida |
| US20050272149A1 (en) * | 2004-06-02 | 2005-12-08 | Life & Brain Gmbh | Therapeutic delivery of adenosine into a tissue |
| WO2009023795A2 (en) * | 2007-08-14 | 2009-02-19 | The Johns Hopkins University | Cell-based compositions and method for treating conditions of the nervous system |
-
2010
- 2010-11-09 JP JP2012538881A patent/JP5952737B2/ja active Active
- 2010-11-09 EP EP17188092.5A patent/EP3269803A3/en not_active Withdrawn
- 2010-11-09 WO PCT/US2010/055956 patent/WO2011059952A1/en not_active Ceased
- 2010-11-09 EP EP10830580.6A patent/EP2499238B1/en active Active
- 2010-11-09 CN CN201080051269.2A patent/CN102686721B/zh active Active
- 2010-11-09 AU AU2010319680A patent/AU2010319680B2/en active Active
- 2010-11-09 PL PL10830580T patent/PL2499238T3/pl unknown
- 2010-11-09 NO NO10830580A patent/NO2499238T3/no unknown
- 2010-11-09 US US13/508,803 patent/US10351823B2/en active Active
- 2010-11-09 ES ES10830580.6T patent/ES2649396T3/es active Active
- 2010-11-09 DK DK10830580.6T patent/DK2499238T3/en active
- 2010-11-09 CN CN201610055313.6A patent/CN105602889A/zh active Pending
- 2010-11-09 CA CA2780541A patent/CA2780541C/en active Active
-
2016
- 2016-02-15 JP JP2016026441A patent/JP6346629B2/ja active Active
-
2018
- 2018-09-19 US US16/135,626 patent/US20190032010A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070037222A1 (en) * | 1997-07-04 | 2007-02-15 | Rao Mahendra S | Lineage restricted glial precursors |
Also Published As
| Publication number | Publication date |
|---|---|
| US10351823B2 (en) | 2019-07-16 |
| JP5952737B2 (ja) | 2016-07-13 |
| PL2499238T3 (pl) | 2018-04-30 |
| EP2499238A1 (en) | 2012-09-19 |
| WO2011059952A1 (en) | 2011-05-19 |
| JP6346629B2 (ja) | 2018-06-20 |
| AU2010319680A1 (en) | 2012-07-05 |
| NO2499238T3 (enExample) | 2018-01-27 |
| US20120230963A1 (en) | 2012-09-13 |
| EP2499238B1 (en) | 2017-08-30 |
| CN105602889A (zh) | 2016-05-25 |
| CN102686721A (zh) | 2012-09-19 |
| JP2013510570A (ja) | 2013-03-28 |
| CN102686721B (zh) | 2016-02-10 |
| ES2649396T3 (es) | 2018-01-11 |
| US20190032010A1 (en) | 2019-01-31 |
| DK2499238T3 (en) | 2017-12-04 |
| EP3269803A3 (en) | 2018-04-25 |
| EP3269803A2 (en) | 2018-01-17 |
| CA2780541A1 (en) | 2011-05-19 |
| JP2016146831A (ja) | 2016-08-18 |
| HK1174953A1 (zh) | 2013-06-21 |
| CA2780541C (en) | 2015-07-14 |
| EP2499238A4 (en) | 2013-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010319680B2 (en) | Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells | |
| TWI586805B (zh) | 獲得及維持在體外易於分化為寡樹突細胞－族系細胞之哺乳類神經幹細胞及／或神經祖源細胞的純或增富族群之培養方法 | |
| Wang et al. | Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination | |
| Faulkner et al. | Human embryonic stem cell-derived oligodendrocyte progenitors for the treatment of spinal cord injury | |
| JP4823689B2 (ja) | 再ミエリン化および脊髄損傷の治療のためのヒト胚性幹細胞に由来するオリゴデンドロサイト | |
| Sandner et al. | Neural stem cells for spinal cord repair | |
| JP5816644B2 (ja) | ヒト胚性幹細胞から、高収率で、神経前駆細胞、神経細胞及び機能性ドーパミン神経細胞を生成する方法 | |
| KR20130092634A (ko) | 신경퇴행성 증상의 치료를 위한 인간 신경 세포의 이식 | |
| Wang et al. | Neurogenic potential of progenitor cells isolated from postmortem human Parkinsonian brains | |
| KR20230165846A (ko) | 도파민성 전구세포 및 사용 방법 | |
| JP2004511266A (ja) | 間葉間質細胞に対する治療的利用法 | |
| US20090136456A1 (en) | Methods of treating neurodegenerative disorders | |
| Liu et al. | Characterization and therapeutic evaluation of a Nestin+ CNP+ NG2+ cell population on mouse spinal cord injury | |
| US20120202745A1 (en) | Adult cerebellum-derived neural stem cells and compositions and methods for producing oligodendrocytes | |
| Khanna et al. | Generation and transplantation of dopaminergic neurons derived from embryonic stem cells | |
| HK1174953B (en) | Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells | |
| JP2018501782A (ja) | 運動ニューロン前駆細胞を持続的に成長させる方法及び医薬組成物 | |
| Canzi | Human stem cells for the treatment of motorneuron diseases: regenerative potential, translatability and development of new biotechnologies. Cellule staminali umane per la cura delle malattie degenerative del motoneurone | |
| Mead | Mesenchymal stem cell therapy for traumatic and degenerative eye disease | |
| HK1093219B (en) | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |